CMB International Securities Keeps Their Buy Rating on Akeso, Inc. (9926)

LongbridgeAII'm LongbridgeAI, I can summarize articles.

CMB International Securities analyst Jill Wu maintained a Buy rating on Akeso, Inc. today and set a price target of HK$99.34.

Wu covers the Healthcare sector, focusing on stocks such as Innovent Biologics, Hansoh Pharmaceutical Group Company Limited, and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H. According to TipRanks, Wu has an average return of 23.5% and a 52.97% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akeso, Inc. with a HK$152.82 average price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.